Skip to main content
Erschienen in: Pathology & Oncology Research 4/2012

01.10.2012 | Research

The Expression of High Mobility Group Box 1 is Associated with Lymph Node Metastasis and Poor Prognosis in Esophageal Squamous Cell Carcinoma

verfasst von: Chen Chuangui, Tang Peng, Yu Zhentao

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

The objective is to explore the expression of high mobility group box 1 (HMGB1) in esophageal squamous cell carcinoma (ESCC) and its relationship with lymph node metastasis and the prognosis of patients as well as possible mechanism. The expression of HMGB1, vascular endothelial growth factor C (VEGF-C) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) in ESCC tissues, which were obtained from 72 patients who underwent radical esophagectomy, was detected through immunohistochemistry, firstly. The correlations between HMGB1 and VEGF-C, and micro-lymphatic vessel density (MLD), and lymph node metastasis, and the prognosis of patients, were analyzed by statistic analysis. The plasmid of small interference RNA (siRNA) targeting HMGB1, giving siHMGB1, was transfected into exponentially growing KYSE150 human esophageal squamous cancer cells and the expression of HMGB1 mRNA and protein was observed by Real-time PCR and Western Blot and the expression of VEGF-C was examined by ELISA. HMGB1 expressed highly in the nuclei and cytoplasm of carcinoma cells as well as the extracellular space in ESCC and was associated with lymph node metastasis, MLD, the expression of VEGF-C, TNM stage and the prognosis of patients (P < 0.05 or P < 0.01). In vitro, siHMGB1 inhibited the expression of HMGB1 mRNA and protein and the secretion of VEGF-C in KYSE150 cells. In ESCC, HMGB1 expresses highly and affects the prognosis of patients through regulating the expression of VEGF-C to promote lymphangiogenesis and lymph node metastasis, and HMGB1 might serve as the marker of progression and potential target for anti-lymphangiogenesis therapy.
Literatur
1.
Zurück zum Zitat Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, O’Dwyer ST, Jayson GC (2003) Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89:426–30PubMedCrossRef Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, O’Dwyer ST, Jayson GC (2003) Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89:426–30PubMedCrossRef
2.
Zurück zum Zitat Aurello P, Rossi Del Monte S, D’Angelo F, Cicchini C, Ciardi A, Bellagamba R, Ravaioli M, Ramacciato G (2009) Vascular endothelial growth factor C and microvessel density in gastric carcinoma: correlation with clinicopathological factors. Our experience and review of the literature. Oncol Res 17:405–11PubMedCrossRef Aurello P, Rossi Del Monte S, D’Angelo F, Cicchini C, Ciardi A, Bellagamba R, Ravaioli M, Ramacciato G (2009) Vascular endothelial growth factor C and microvessel density in gastric carcinoma: correlation with clinicopathological factors. Our experience and review of the literature. Oncol Res 17:405–11PubMedCrossRef
3.
Zurück zum Zitat Shimoda H, Takahashi Y, Kajiwara T, Kato S (2003) Demonstration of the rat lymphatic vessels using immunohistochemistry and in situ hybridization for 5′- nucleotidase. Biomed Res 24:51–7 Shimoda H, Takahashi Y, Kajiwara T, Kato S (2003) Demonstration of the rat lymphatic vessels using immunohistochemistry and in situ hybridization for 5′- nucleotidase. Biomed Res 24:51–7
4.
Zurück zum Zitat Liu P, Chen W, Zhu H, Liu B, Song S, Shen W, Wang F, Tucker S, Zhong B, Wang D (2009) Expression of VEGF-C correlates with a poor prognosis based on analysis of prognostic factors in 73 patients with esophageal squamous cell carcinomas. Jpn J Clin Oncol 39:644–50PubMedCrossRef Liu P, Chen W, Zhu H, Liu B, Song S, Shen W, Wang F, Tucker S, Zhong B, Wang D (2009) Expression of VEGF-C correlates with a poor prognosis based on analysis of prognostic factors in 73 patients with esophageal squamous cell carcinomas. Jpn J Clin Oncol 39:644–50PubMedCrossRef
5.
Zurück zum Zitat Czura CJ, Wang H, Tracey KJ (2001) Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 7:315–21PubMedCrossRef Czura CJ, Wang H, Tracey KJ (2001) Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 7:315–21PubMedCrossRef
6.
Zurück zum Zitat Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G (2010) Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 136:677–84PubMedCrossRef Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G (2010) Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 136:677–84PubMedCrossRef
7.
Zurück zum Zitat Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164:441–49PubMedCrossRef Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164:441–49PubMedCrossRef
8.
Zurück zum Zitat Gnanasekar M, Thirugnanam S, Ramaswamy K (2009) Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 34:425–431PubMed Gnanasekar M, Thirugnanam S, Ramaswamy K (2009) Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 34:425–431PubMed
9.
Zurück zum Zitat Tang D, Kang R, Zeh HJ 3rd, Lotze MT (2010) High-mobility group box 1 and cancer. Biochim Biophys Acta 1799:131–40PubMedCrossRef Tang D, Kang R, Zeh HJ 3rd, Lotze MT (2010) High-mobility group box 1 and cancer. Biochim Biophys Acta 1799:131–40PubMedCrossRef
10.
Zurück zum Zitat Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, Tatsumoto N, Fujii K, Ohmori H, Kuniyasu H (2009) Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 76:155–62PubMedCrossRef Kusume A, Sasahira T, Luo Y, Isobe M, Nakagawa N, Tatsumoto N, Fujii K, Ohmori H, Kuniyasu H (2009) Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology 76:155–62PubMedCrossRef
11.
Zurück zum Zitat Moriwaka Y, Luo Y, Ohmori H, Fujii K, Tatsumoto N, Sasahira T, Kuniyasu H (2010) HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 77:17–23PubMedCrossRef Moriwaka Y, Luo Y, Ohmori H, Fujii K, Tatsumoto N, Sasahira T, Kuniyasu H (2010) HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology 77:17–23PubMedCrossRef
12.
Zurück zum Zitat Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK, Kim H (2009) Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest 89:948–59PubMedCrossRef Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, Yoo JS, Paik YK, Kim H (2009) Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest 89:948–59PubMedCrossRef
13.
Zurück zum Zitat Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S, Bullerdiek J (2005) Angiogenetic signaling through hypoxia HMGB1: an angiogenetic switch molecule. Am J Path 166:1259–63PubMedCrossRef Schlueter C, Weber H, Meyer B, Rogalla P, Röser K, Hauke S, Bullerdiek J (2005) Angiogenetic signaling through hypoxia HMGB1: an angiogenetic switch molecule. Am J Path 166:1259–63PubMedCrossRef
14.
Zurück zum Zitat Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis –correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis –correlation in invasive breast carcinoma. N Engl J Med 324:1–8PubMedCrossRef
15.
Zurück zum Zitat Chen C, Sun J, Liu G, Chen J (2009) Effect of small interference RNA targeting HIF-1α mediated by rAAV combined L-ascorbate on pancreatic tumors in athymic mice. Pathol Oncol Res 15:109–14PubMedCrossRef Chen C, Sun J, Liu G, Chen J (2009) Effect of small interference RNA targeting HIF-1α mediated by rAAV combined L-ascorbate on pancreatic tumors in athymic mice. Pathol Oncol Res 15:109–14PubMedCrossRef
16.
Zurück zum Zitat Tuomela J, Valta M, Seppänen J, Tarkkonen K, Väänänen HK, Härkönen P (2009) Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer 9:362PubMedCrossRef Tuomela J, Valta M, Seppänen J, Tarkkonen K, Väänänen HK, Härkönen P (2009) Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer 9:362PubMedCrossRef
17.
Zurück zum Zitat Zeh HJ 3rd, Lotze MT (2005) Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 28:1–9PubMedCrossRef Zeh HJ 3rd, Lotze MT (2005) Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 28:1–9PubMedCrossRef
18.
Zurück zum Zitat Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, Stolz DB, Zeh HJ 3rd, Lotze MT (2007) Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 81:75–83PubMedCrossRef Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, Stolz DB, Zeh HJ 3rd, Lotze MT (2007) Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 81:75–83PubMedCrossRef
Metadaten
Titel
The Expression of High Mobility Group Box 1 is Associated with Lymph Node Metastasis and Poor Prognosis in Esophageal Squamous Cell Carcinoma
verfasst von
Chen Chuangui
Tang Peng
Yu Zhentao
Publikationsdatum
01.10.2012
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2012
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-012-9539-3

Weitere Artikel der Ausgabe 4/2012

Pathology & Oncology Research 4/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.